Meeting NewsVideo

VIDEO: Studies may lead to ‘era’ where chemotherapy is not needed for lymphoma subtype

ATLANTA — Two long-term follow-up studies presented at the ASH Annual Meeting and Exposition may indicate a future where patients with mantle cell lymphoma can be effectively managed without the use of chemotherapy, according to Jonathon B. Cohen, MD, MS, medical director of infusion services at Winship Cancer Institute of Emory University.

Cohen, who co-moderated the session that included both follow-up studies, spoke with HemOnc Today about how the results from Ruan and colleagues, as well as Hoster and colleagues demonstrate benefits with certain novel therapies in patients with mantle cell lymphoma.

“We continue to see a significant OS benefit for rituximab (Rituxan; Genentech, Biogen) maintenance after R-CHOP for previously untreated mantle cell lymphoma patients,” he said. “This is very exciting as many of these patients that were not previously candidates for aggressive therapy had inferior outcomes and now that we're starting to see that R-CHOP followed by rituximab maintenance can still result in prolonged remission, it provides a lot of excitement for those physicians that are treating patients that aren't eligible for the most aggressive therapies.

Reference:

Hoster E, et al. Abstract 153. Presented at: ASH Annual Meeting and Exposition; Dec. 9-12, 2017; Atlanta.

Ruan J, et al. Abstract 154. Presented at: ASH Annual Meeting and Exposition; Dec. 9-12, 2017; Atlanta.

Disclosures: Cohen reports no relevant financial disclosures.

ATLANTA — Two long-term follow-up studies presented at the ASH Annual Meeting and Exposition may indicate a future where patients with mantle cell lymphoma can be effectively managed without the use of chemotherapy, according to Jonathon B. Cohen, MD, MS, medical director of infusion services at Winship Cancer Institute of Emory University.

Cohen, who co-moderated the session that included both follow-up studies, spoke with HemOnc Today about how the results from Ruan and colleagues, as well as Hoster and colleagues demonstrate benefits with certain novel therapies in patients with mantle cell lymphoma.

“We continue to see a significant OS benefit for rituximab (Rituxan; Genentech, Biogen) maintenance after R-CHOP for previously untreated mantle cell lymphoma patients,” he said. “This is very exciting as many of these patients that were not previously candidates for aggressive therapy had inferior outcomes and now that we're starting to see that R-CHOP followed by rituximab maintenance can still result in prolonged remission, it provides a lot of excitement for those physicians that are treating patients that aren't eligible for the most aggressive therapies.

Reference:

Hoster E, et al. Abstract 153. Presented at: ASH Annual Meeting and Exposition; Dec. 9-12, 2017; Atlanta.

Ruan J, et al. Abstract 154. Presented at: ASH Annual Meeting and Exposition; Dec. 9-12, 2017; Atlanta.

Disclosures: Cohen reports no relevant financial disclosures.

    See more from Discoveries from ASH Non-Hodgkin Lymphoma